Why the study?
Does isosorbide-5-mononitrate alter the plasma cGMP response to exercise in coronary patients and healthy controls?
Does isosorbide-5-mononitrate alter the plasma cGMP response to exercise in coronary patients and healthy controls?
Administration of isosorbide-5-mononitrate blunts the normal exercise-induced increase in plasma cGMP in both coronary patients and healthy controls.
Answers are grounded in this paper and cite their sources.
IS-5-MN blunts exercise cGMP rise in coronary patients and controls; hypothesis-generating for nitrate effects on exercise signaling.
Nitric oxide (NO) and atrial natriuretic peptide (ANP) relax vascular smooth muscle increasing levels of cyclic guanosine 3':5' monophosphate (cGMP). Nitrovasodilators act as exogenous nitric oxide donors. The aim of this study was to ascertain the response of cGMP to exercise without medication and after the administration of 20 mg of isosorbide-5-mononitrate (IS-5-MN) in coronary patients (n = 8) and healthy control subjects (n = 9). A third group of 10 normal volunteers was studied to test plasma cGMP response to second exercise test without IS-5-MN administration. Plasma cGMP increased significantly in both patients (P < 0.02) and controls (P < 0.01) after the first ergometry. After IS-5-MN administration, plasma cGMP did not increase either before or after exercise. In normal volunteers without IS-5-MN plasma cGMP increased significantly after first (P < 0.004) and second (P < 0.0008) exercise test. In conclusion, plasma cGMP increases during exercise. Administration of IS-5-MN does not raise plasma cGMP and neither does performance of further exercise after its administration.
No takes yet. Share an insight, caveat, or question.
Berrazueta et al. (1995) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: